Zobrazeno 1 - 10
of 120
pro vyhledávání: '"ensitrelvir"'
Publikováno v:
Infection and Drug Resistance, Vol Volume 17, Pp 5011-5015 (2024)
Masafumi Seki, Chie Kubosawa, Makoto Ono, Fumitaka Kamoshita, Atsuko Shimizu, Kotaro Mitsutake Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, JapanCorrespondence: Masafumi
Externí odkaz:
https://doaj.org/article/9c577554de274623a6ebe79d098ed4b9
Autor:
Daichi Yamaguchi, Masaya M. Saito, Ayano Hata, Ryosuke Shimizu, Shogo Miyazawa, Takamichi Baba, Ryuji Kubota, Yoshitake Kitanishi
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 11, Pp 2377-2393 (2024)
Abstract Introduction Mathematical modeling can provide quantitative understanding of the viral dynamics and viral reduction effects of drugs and enable simulations of the dynamics in various scenarios. In this study, a drug effect model of ensitrelv
Externí odkaz:
https://doaj.org/article/e4f26f60fa3b4dfa85ee6cc100c70507
Autor:
Takahiro Takazono, Satoki Fujita, Takuji Komeda, Shogo Miyazawa, Yuki Yoshida, Yoshitake Kitanishi, Masahiro Kinoshita, Satoshi Kojima, Huilian Shen, Takeki Uehara, Naoki Hosogaya, Naoki Iwanaga, Hiroshi Mukae
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 11, Pp 2463-2467 (2024)
Externí odkaz:
https://doaj.org/article/d330b484c3574a8db9aa58b61448ddbc
Autor:
Hanako Naganawa, Yoshiki Katada, Shunsaku Nakagawa, Keisuke Umemura, Hiroki Ishimura, Moto Kajiwara, Hiroki Endo, Mitsuhiro Sugimoto, Yurie Katsube, Kinuka Kotani, Saki Ohta, Daiki Hira, Masahiro Tsuda, Yuki Kita, Takashi Kobayashi, Tomohiro Terada
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-6 (2024)
Abstract Background Among the oral antivirals used for treating patients with mild-to-moderate novel coronavirus disease 2019 (COVID-19), nirmatrelvir/ritonavir (NMV/RTV) and ensitrelvir (ESV) are inhibitors of cytochrome P450 (CYP) 3A, and therefore
Externí odkaz:
https://doaj.org/article/a725f98f1f0545a89762afa6a3dc25bc
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Long COVID, or Post-Acute Sequelae of COVID-19 (PASC), was characterized by persistent symptoms such as fatigue, shortness of breath, and cognitive impairments. These symptoms, emerging one to 2 months post-infection and persisting for several months
Externí odkaz:
https://doaj.org/article/4821f2c31891480fb8b1891fd74a5e22
Autor:
Takahiro Takazono, Satoki Fujita, Takuji Komeda, Shogo Miyazawa, Yuki Yoshida, Yoshitake Kitanishi, Masahiro Kinoshita, Satoshi Kojima, Huilian Shen, Takeki Uehara, Naoki Hosogaya, Naoki Iwanaga, Hiroshi Mukae
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 8, Pp 1821-1833 (2024)
Abstract Introduction This study aimed to evaluate the effectiveness of ensitrelvir, an oral antiviral, in reducing hospitalization risk in outpatients at high-risk for severe COVID-19 during the Omicron era. Methods This was a retrospective study us
Externí odkaz:
https://doaj.org/article/7413e1399c5245c6a312d602e8452527
Autor:
Nakashima, Masaaki a, Nobori, Haruaki a, Kuroda, Takayuki a, Shimba, Alice a, Miyagawa, Satoshi a, Hayashi, Akane b, Matsumoto, Kazumi b, Yoshida, Mei b, Baba, Kaoru b, Kato, Teruhisa a, Fukao, Keita a, ⁎
Publikováno v:
In Antiviral Research December 2024 232
Publikováno v:
Emerging Infectious Diseases, Vol 30, Iss 6, Pp 1289-1291 (2024)
Using the GISAID EpiCoV database, we identified 256 COVID-19 patients in Japan during March 31–December 31, 2023, who had mutations in the SARS-CoV-2 nonstructural protein 5 conferring ensitrelvir resistance. Ongoing genomic surveillance is require
Externí odkaz:
https://doaj.org/article/7f113a35f2c14c909273ad743c0db302
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 3, Pp 597-607 (2024)
Abstract Introduction Ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, shows efficacy and safety in participants with mild to moderate COVID-19. Since urinary recovery of ensitrelvir ranged from 12.9% to 21.8% across dose groups
Externí odkaz:
https://doaj.org/article/01cf06d8b3224805a579c60358d0c242
Autor:
Hideharu Hagiya
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 11, Pp 2461-2462 (2024)
Externí odkaz:
https://doaj.org/article/95f7b8bc9dfc4f32ad027c5d6ee80994